{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:08:06Z","timestamp":1696262886952},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ijcard.2012.11.110","type":"journal-article","created":{"date-parts":[[2012,12,27]],"date-time":"2012-12-27T03:41:27Z","timestamp":1356579687000},"page":"396-397","source":"Crossref","is-referenced-by-count":9,"title":["Exploring the reduction in myocardial infarctions in the PLATO trial: Which patients benefited on ticagrelor vs. clopidogrel?"],"prefix":"10.1016","volume":"165","author":[{"given":"James J.","family":"DiNicolantonio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor L.","family":"Serebruany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2012.11.110_bb0005","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"61","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.11.110_bb0010","unstructured":"FDA ticagrelor review of complete response \u2014 drug approval package. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022433Orig1s000TOC.cfm. In: Administration UFaD, ed. Silver Spring, MD: US Department of Health and Human Services, 2011."},{"key":"10.1016\/j.ijcard.2012.11.110_bb0015","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1161\/STROKEAHA.112.668988","article-title":"Comparing ticagrelor versus clopidogrel in patients with a history of cerebrovascular disease: a net clinical harm?","volume":"43","author":"DiNicolantonio","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2012.11.110_bb0020","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1160\/TH10-12-0807","article-title":"Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified","volume":"105","author":"Serebruany","year":"2011","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ijcard.2012.11.110_bb0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijcard.2012.09.113","article-title":"Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: challenging PLATO mortality rates","volume":"164","author":"DiNicolantonio","year":"2013","journal-title":"Int J Cardiol"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527312016233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527312016233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T21:31:40Z","timestamp":1539984700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527312016233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0167527312016233"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2012.11.110","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}